drugset / Trial / NCT01510704
Phase II Dose-ranging Study of APD421 in PONV
RandomizedParallel-groupQuadruple-blindPrevention
Summary
To assess the efficacy and safety of different doses of APD421 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.
Timeline
- Start
- 2012-01
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amisulpride | Small molecule | 1 mg | Intravenous |
| Subject | Amisulpride | Small molecule | 5 mg | Intravenous |
| Subject | Amisulpride | Small molecule | 20 mg | Intravenous |
Indications
No indication recorded.